3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE

• Main Authors: ASHWORTH, ALAN, KEY, REBEKAH ELISABETH, BAYFORD, MELANIE JAYNE, ELLIOTT, RICHARD JAMES ROWLAND, FIRTH-CLARK, STUART, LORD, CHRISTOPHER JAMES, PORTER, RODERICK, PERRIOR, TREVOR ROBERT, BOFFEY, RAYMOND JOHN, NICULESCU-DUVAZ, DAN, JARVIS, ASHLEY NICHOLAS
• Format: Patent
• Language: English; French
• Published: 12.09.2013
• Subjects: CHEMISTRY; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 3-aryl-5-substituted- 2H-isoquinolin-1-one compounds that, inter alia, inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.) and/or Wnt signalling. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to inhibit Wnt signalling; to treat disorders that are ameliorated by the inhibition of PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to treat disorders that are ameliorated by the inhibition of Wnt signalling; to treat proliferative conditions such as cancer, etc. La présente invention concerne d'une manière générale le domaine des composés thérapeutiques. Plus spécifiquement, la présente invention se rapporte à certains composés 3-aryl -5-substitué -2 H-isoquinolin -1-one qui, entre autres, inhibent PARP (par exemple, PARP1, TNKS1, TNKS2, etc.) et/ou de signalisation Wnt. La présente invention concerne également des compositions pharmaceutiques comprenant ces composés à la fois in vitro et in vivo pour inhiber la signalisation Wnt afin de traiter des troubles qui sont améliorés par l'inhibition de PARP (par exemple, PARP1, TNKS1, TNKS2, etc.), de traiter des troubles qui sont améliorés par l'inhibition de la signalisation Wnt et de traiter des états prolifératifs tels que le cancer, etc.